12:00 AM
 | 
Feb 22, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

XTL-001: Phase I

Preliminary data from a Phase I trial in 15 HBV-infected patients showed that a single dose of XTL-001 ranging from 0.26...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >